Wanted: Marketing strategy for MannKind's long-time-coming inhaled insulin

MannKind's ($MNKD) third-time's-the-charm win on its inhaled insulin Afrezza isn't the finish line for the long-suffering company. Its quest to gain FDA approval may be over, but the marketing job is just beginning. Report